PedAM
Pediatric Disease Annotations & Medicines
| rosacea | ||||
| Disease ID | 896 |
|---|---|
| Disease | rosacea |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:24) HP:0010783 | Erythema | 12 HP:0001041 | Blushing | 7 HP:0200039 | Pustules | 2 HP:0001004 | Lymphatic obstruction | 2 HP:0010628 | Facial palsy, unilateral or bilateral | 2 HP:0001677 | Coronary artery disease | 1 HP:0001061 | Acne | 1 HP:0000739 | Anxiety | 1 HP:0000969 | Dropsy | 1 HP:0200034 | Papule | 1 HP:0002958 | Immune dysregulation | 1 HP:0001051 | Seborrheic dermatitis | 1 HP:0012804 | Corneal ulceration | 1 HP:0002597 | Abnormality of blood vessels | 1 HP:0100280 | Morbus Crohn | 1 HP:0001009 | Telangiectases | 1 HP:0001047 | Atopic dermatitis | 1 HP:0001251 | Ataxia | 1 HP:0100512 | Vitamin D deficiency | 1 HP:0000491 | Corneal inflammation | 1 HP:0000559 | Corneal scarring | 1 HP:0003765 | Psoriasis | 1 HP:0003493 | Elevated antinuclear antibody | 1 HP:0100699 | Scarring | 1 |
| Disease ID | 896 |
|---|---|
| Disease | rosacea |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:7) C0041834 | erythema | 9 C0016382 | flushing | 6 C0009450 | infection | 2 C1402315 | vascular lesions | 1 C0314719 | dry eye | 1 C0039446 | telangiectasia | 1 C0039446 | telangiectasias | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs763035 | 25695682 | 56244 | BTNL2 | umls:C0035854 | BeFree | Exploratory immunohistochemical analysis of HLA-DRA and BTNL2 expression in papulopustular rosacea lesions from six individuals, including one with the rs763035 variant, revealed staining in the perifollicular inflammatory infiltrate of rosacea for both proteins. | 0.000271442 | 2015 | NA | 6 | 32427068 | G | A |
| rs763035 | 25695682 | 3122 | HLA-DRA | umls:C0035854 | BeFree | Exploratory immunohistochemical analysis of HLA-DRA and BTNL2 expression in papulopustular rosacea lesions from six individuals, including one with the rs763035 variant, revealed staining in the perifollicular inflammatory infiltrate of rosacea for both proteins. | 0.000271442 | 2015 | NA | 6 | 32427068 | G | A |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:8) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0035854 | azelaic acid | C010038 | - | rosacea | MESH:D012393 | therapeutic | 17472690 | ||
| C0035854 | azithromycin | D017963 | 83905-01-5 | rosacea | MESH:D012393 | therapeutic | 17244346 | ||
| C0035854 | doxycycline | D004318 | 564-25-0 | rosacea | MESH:D012393 | therapeutic | 19588640 | ||
| C0035854 | peginterferon alfa-2b | C417083 | - | rosacea | MESH:D012393 | marker/mechanism | 14558405 | ||
| C0035854 | pimecrolimus | C117268 | - | rosacea | MESH:D012393 | marker/mechanism | 12920379 | ||
| C0035854 | pimecrolimus | C117268 | - | rosacea | MESH:D012393 | therapeutic | 17373975 | ||
| C0035854 | ribavirin | D012254 | 36791-04-5 | rosacea | MESH:D012393 | marker/mechanism | 14558405 | ||
| C0035854 | tacrolimus | D016559 | 109581-93-3 | rosacea | MESH:D012393 | marker/mechanism | 15096374 | ||
FDA approved drug and dosage information(Total Drugs:2) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D012393 | elidel | pimecrolimus | 1% | CREAM;TOPICAL | Prescription | None | Yes | Yes |
| MESH:D012393 | elidel | pimecrolimus | 1% | CREAM;TOPICAL | Prescription | None | Yes | Yes |
FDA labeling changes(Total Drugs:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D012393 | 12/13/2001 | elidel | pimecrolimus | Treatment of mild/moderate atopic dermatitis | Indicated for short-term and intermittent long-term therapy for mild to moderate atopic dermatitis in non-immunocompromised patients 2 years and older Not recommended for use in pediatric patients less than 2 years of age. Infants on Elidel Cream had an increased incidence of some adverse events compared to vehicle which included pyrexia, URI, nasopharyngitis, gastroenteritis, otitis media, and diarrhea. | Labeling | B | - | - | - | Novartis | 09/24/2001 | FALSE' |
| MESH:D012393 | 12/13/2001 | elidel | pimecrolimus | Treatment of mild/moderate atopic dermatitis | Indicated for short-term and intermittent long-term therapy for mild to moderate atopic dermatitis in non-immunocompromised patients 2 years and older Not recommended for use in pediatric patients less than 2 years of age. Infants on Elidel Cream had an increased incidence of some adverse events compared to vehicle which included pyrexia, URI, nasopharyngitis, gastroenteritis, otitis media, and diarrhea. | Labeling | B | - | - | - | Novartis | 09/24/2001 | FALSE' |